News

Holdings in Company  - TR1 notification was received from Spreadex Limited.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 23 November 2018 it purchased 1,000,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.16p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 64,946,734 equivalent to 22% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 22 November 2018 it purchased 500,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.24p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 63,946,734 equivalent to 21.66% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 19 November 2018 it purchased 500,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.42p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 63,446,734 equivalent to 21.49% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 16 November 2018 it purchased 500,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.42p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 62,946,734 equivalent to 21.32% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 12 November 2018 it purchased 1,000,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 62,446,734 equivalent to 21.15% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 8 November 2018 that it purchased 313,957 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.49p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 61,446,734 equivalent to 20.82% of Proteome Sciences' total issued share capital.

The Company is pleased to announce that recognised revenues from services during the third quarter were the strongest this year and early evidence of a characteristically stronger fourth quarter suggests that the value of committed work orders in 2018 should be more than double that achieved in 2017.  However, overall performance remains behind plan and full year service revenues will likely be in line with the previous year reflecting the time taken to execute orders.  Sales and marketing activities are prominent despite a limited budget, with high volumes of customer calls and requests for quotations as well as exhibitions in Germany, US, Denmark, UK and Spain during the fourth quarter.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on the 9 and 10 October 2018 it purchased 100,000 and 180,790 Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at 3.66p per Ordinary Share (the “Purchase”).  Following the Purchase, Vulpes has a total direct and indirect interest in 61,132,777 equivalent to 20.71% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 9 October 2018 that on the 5 and 8 October 2018 it purchased 54,000 and 460,899  Ordinary Shares of 1p, respectively, in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,851,987 equivalent to 20.62% of Proteome Sciences' total issued share capital.